Dermapharm Holding SE raises EBITDA forecast for the full year 2021

Grünwald, December 16, 2021 - Dermapharm Holding SE ("Dermapharm"), a high-growth manufacturer of branded pharmaceuticals, is raising its guidance for adjusted Group EBITDA. The Management Board now expects an improvement of 70% to 75% compared to the previous year and confirms the growth in Group sales of 15% to 20%.

In view of the very good operational business development to date and the increasing transparency at the end of the year, the Executive Board is increasing the forecast for adjusted Group EBITDA for 2021. The Executive Board now expects growth in adjusted Group EBITDA of 70% to 75% (previously: 50% to 60%).

On the basis of shifts in the contribution of the segments "branded pharmaceuticals and other healthcare products", "herbal extracts" and "parallel import business", Dermapharm confirms its sales expectations and continues to anticipate an increase in consolidated sales of 15% to 20%.

The main growth driver for the very good EBITDA development is the proportionally faster growing segment "branded pharmaceuticals and other healthcare products", e.g. with products to strengthen the immune system and the successful vaccine production in cooperation with BioNTech SE.

"In addition to raising our EBITDA forecast, we expect our successful development in Germany and abroad and in the vaccine cooperation with BioNTech SE to continue in 2022. We are therefore expanding our production capacities," said Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE. Dermapharm has invested in production facilities for filling, packaging and quality control of vaccines. "In time for the fight against the Omikron variant, we have extended production capacities and expect a significant increase in vaccine production compared to the previous year," Dr Feldmeier continues.

Company profile:

Dermapharm - Pharmaceutical Excellence "Made in Germany"

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

In the "Herbal extracts" segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm's business model also includes the "Parallel import business" segment that operates under the "axicorp" brand. Based on revenue, Dermapharm was among the top five parallel import companies in Germany in 2020.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
E-mail: ir@dermapharm.com